We write regarding the administration of the Food and Drug Administration’s (FDA’s) Pediatric Rare Disease Priority Review Voucher (PRV) program, particularly the decision by the previous administration to deny a PRV for a one-time administered novel curative gene therapy that treats sickle cell disease.
Sen. Scott urges FDA to reconsider gene therapy decision.
Share
More from Tim Scott
I will say on the other side, it is not going to the past, it's going to a different, an alternate universe.
The Biden administration’s plan would have made it harder to get a mortgage, harder to start a business, and more expensive to make ends meet.
I have not seen and heard of an endorsement yet coming out of the White House.
Every student deserves a fair shot at any college or university regardless of his or her family’s background and connections to the institution.
Other voices in this conversation
